Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1172 participants.
Also called NCT07468448
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 1,172 participants
- Registry
-
NCT07468448
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07468448. Randomized; quadruple masking; primary purpose prevention. Start 2026-09-30 (anticipated); primary completion 2029-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)
- Acronym
- CATIS-ICAS
- Condition
- Ischemic Stroke
- Condition
- Intracranial Atherosclerosis
- Intervention (Drug)
- Rivaroxaban
- Intervention (Drug)
- ASA
- Lead sponsor
- Population Health Research Institute
Record details
- Record id
cardio:ct-nct07468448- Content hash
0bf11bcac81d93177740e4c53e6b1cbfb44feab5004a8d9241a19a72b10e4d9b